European Journal of Clinical Pharmacology

, Volume 28, Issue 4, pp 463–467 | Cite as

Pharmacokinetics of ceftizoxime

  • U. Gundert-Remy
  • R. Hildebrandt
  • A. Stiehl
  • P. Schlegel


The kinetics of ceftizoxime, a newly developed cephalosporin, were evaluated in 6 healthy subjects, with respect to its excretory pathways especially by the biliary route. Total, renal and biliary clearance were determined at two different steady states. Steady state was achieved by constant intravenous infusion (604.1 mg/h) over 6 h after an initial loading dose (750 mg); 1.5 h after discontinuation of that infusion, a further infusion was commenced at a lower rate (284 mg/h) over 3 h, the second steady state being reached 0.5 to 1.0 h later.

The drug was mainly excreted by the kidneys (56.7 to 92.9% of the dose). Biliary excretion, measured by the duodenal perfusion and marker dilution technique, was low (0.2 to 7.8% of the dose). Urinary and biliary excretion as well as total clearance were not dose-dependent. However, there was pronounced interindividual variation in total (35.2 to 236 ml/min) and renal clearance (10.6 to 208 ml/min), which could both be explained by varying interindividual urinary flow rates (mean flow rate: 0.99 ml/min to 3.14 ml/min).

Intraindividual variation in renal clearance was less pronounced, but in the same subject changes in renal clearance were correlated with changes in urinary flow rate. From the varying renal clearance, which exceeded the glomerular filtration rate at high urinary flow rates and was below it at low urinary flow rates, it can be concluded that, in addition to glomerular filtration, tubular secretion and tubular reabsorption are involved in the renal excretion of ceftizoxime.

The half-life calculated from two point estimates after discontinuation of the infusion at the higher rate tended to be longer in subjects with high total clearance (e. g. 1.4 h, clearance 223 ml/min) and shorter in subjects with low total clearance (e.g. 0.85 h, clearance 35.2 ml/min). From this it is concluded that the true half-life was not observed after discontinuation of the infusion.

Key words

ceftizoxime cephalosporins renal excretion tubular reabsorption tubular secretion healthy volunteers biliary excretion clearance studies 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Arvidsson A, Borga O, Alván G (1979) Renal excretion of cephapirin and cephaloridine: evidence for saturable tubular reabsorption. Clin Pharmacol Ther 25: 870–876Google Scholar
  2. 2.
    Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41Google Scholar
  3. 3.
    Dubb J, Actor P, Pitkin D, Alexander F, Familiar R, Ehrlich S, Stote R (1982) Ceftizoxime kinetics and renal handling. Clin Pharmacol Ther 31: 516–521Google Scholar
  4. 4.
    Gerding DN, Van Etta LL, Peterson LR (1982) Role of serum protein binding and multiple antibiotic doses in the extravascular distribution of ceftizoxime and cefotaxime. Antimicrobiol Agents Chemother 22: 844–847Google Scholar
  5. 5.
    Gundert-Remy U, Frohnapfel F, Jourdan W, Weber E, Stiehl A (1982) Estimation of biliary excretion of ureidopencillins in healthy volunteers using marker dilution technique. Br J Clin Pharmacol 13: 795–802Google Scholar
  6. 6.
    Helm EB, Wurbs D, Haag R, Beutele D, Shah PM (1982) Elimination of bacteria in biliary tract infections during ceftizoxime therapy. Infection 10: 67–70Google Scholar
  7. 7.
    Nakashima N, Suzuki K, Hashimoto H, Niskijiama K (1981) Phase I study of ceftizoxime, a new cephalosporin. Single dose study. J Clin Pharmacol 21: 388–395Google Scholar
  8. 8.
    Onkawa M, Okasho A, Sugata T, Kuroda K (1982) Elimination kinetic of ceftizoxime in humans with and without renal insufficiency. Antimicrobiol Agents Chemother 22: 308–311Google Scholar
  9. 9.
    Peterson LR, Gerding DN, Van Etta LL, Eckfeld JH, Larson TA (1982) Pharmacokinetics, protein binding and extravascular distribution of ceftizoxime in normal subjects. Antimicrobiol Agents Chemother 22: 878–881Google Scholar

Copyright information

© Springer-Verlag 1985

Authors and Affiliations

  • U. Gundert-Remy
    • 1
    • 4
  • R. Hildebrandt
    • 1
  • A. Stiehl
    • 2
  • P. Schlegel
    • 3
  1. 1.Abteilungen Klinische PharmakologieHeidelbergFederal Republic of Germany
  2. 2.GastroenterologieMedizinische UniversitätsklinikHeidelbergFederal Republic of Germany
  3. 3.Gesellschaft für microbiologische und biologisch-chemische UntersuchungenFreiburgFederal Republic of Germany
  4. 4.Institut für Arzneimittel des BundesgesundheitsamtesBerlin 33

Personalised recommendations